Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL9596992 | 0.94 | SCN9A (0.45) | SLC6A4SLC6A2SLC6A3OPRM1OPRD1 | |
| SCHEMBL10848810 | 0.86 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3OPRM1OPRK1 | |
| SCHEMBL1769006 | 0.85 | SLC6A3 (0.46) | SLC6A4SLC6A2SLC6A3OPRM1SCN9A | |
| SCHEMBL795699 | 0.84 | ACHE (0.45) | OPRM1OPRD1OPRK1OPRL1SCN9A | |
| SCHEMBL9596460 | 0.83 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3OPRM1OPRD1 | |
| SCHEMBL9596721 | 0.83 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3OPRM1OPRD1 | |
| SCHEMBL1925083 | 0.83 | OPRM1 (0.52) | SLC6A4SLC6A2SLC6A3OPRM1OPRD1 | |
| SCHEMBL1740319 | 0.83 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3OPRM1OPRD1 | |
| SCHEMBL72584 | 0.82 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3OPRM1OPRD1 | |
| SCHEMBL20068832 | 0.81 | HRH3 (0.50) | SLC6A4SLC6A2SLC6A3MGLLABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8618117-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2649061-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm S.p.A. (IT) | 2013-10-16 | — | — | EP | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1261602-A1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-12-04 | — | — | EP | disclosed |
| EP-1228065-A1 | (INDOL-3-YL)-CYCLOALKYL]-3-SUBSTITUTED AZETIDINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Wyeth (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001066540-A1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-09-13 | — | — | WO | disclosed |
| US-6245799-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS; ANXIOLYTIC AGENTS | AMERICAN HOME PRODUCTS CORP | 2001-06-12 | — | — | US | disclosed |
| WO-2001034598-A1 | [(INDOL-3-YL)-CYCLOALKYL]-3-SUBSTITUTED AZETIDINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WYETH (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-0131435-B1 | PROCESS FOR PREPARING 3-PHENOXY-1-AZETIDINES AND CARBOXAMIDE DERIVATIVES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1987-10-07 | — | — | EP | disclosed |
| US-4594189-A | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A. H. ROBINS COMPANY, INC. (US) | 1986-06-10 | — | — | US | disclosed |
| EP-0131435-A1 | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | SLC6A4 640/4885SLC6A2 411/4885SLC6A3 122/4885 |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | SLC6A4 640/4885SLC6A2 411/4885SLC6A3 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.